Predicting response and resistance to cancer immunotherapy

“Emerging liquid biopsy biomarkers: Predicting response and resistance to cancer immunotherapy“

Speakers: Genevieve Boland, M.D., Ph.D., FACS Massachusetts General HospitalBoston, MA
Evert Jan Van Limbergen, M.D., Ph.D.Maastro Clinic Maastricht, The Netherlands

During the webinar, the speakers:

• Explain how whole-plasma proteomic profiling in melanoma and non–small cell lung cancer (NSCLC) patients enables the discovery of blood-based biomarkers to predict immunotherapy responses, including resistance and toxicity.
• Describe how changes in immune activation during immunotherapy and radiation could be tracked by differentially expressed plasma proteins.
• Clarify how proteomic and transcriptomic biomarkers along with tumor-based analyses can drive patient selection and provide clinically actionable information.
• Demonstrate the relationship of plasma biomarkers to overall survival and progression-free survival in patients with advanced melanoma undergoing immunotherapy.
  Answer viewer questions during the live broadcast.